Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: A randomized, double-blind, vehicle-controlled trial

Journal of Drugs in Dermatology

Volumn 12, Issue 1, 2013, Pages 92-98

  Menter, Alan ^a   Gold, Linda Stein ^b   Bukhalo, Michael ^c   Grekin, Steven ^d   Kempers, Steven ^e   Boyce, Brent M ^f   Ganslandt, Cecilia ^g   Villumsen, John ^g   Mark Lebwohl MD, ^h  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c Altman Dermatology Associates   (United States)

^d Grekin Skin Institute   (United States)

^e Minnesota Clinical Study Center   (United States)

^f Great Lakes Research Group Inc   (United States)

^g LEO PHARMA A S   (Denmark)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL;

ADULT; APPLICATION SITE PAIN; ARTICLE; BODY SURFACE; CELLULITIS; CONTACT DERMATITIS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN IRRITATION; SUSPENSION; TRUNK; ULTRAVIOLET B RADIATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; PHARMACEUTICAL VEHICLES; PSORIASIS; QUALITY OF LIFE; SKIN; SUSPENSIONS;

EID: 84873475836     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-284.
3. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
4. Menter A, Korman NJ, Elmets CA, et al; American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section
5. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
6. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;(2):CD005028.
7. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48-54.
8. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.
9. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59(3):455-463.
10. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170-176.
11. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, doubleblind, exploratory study. Eur J Dermatol. 2010;20(4):465-471.
12. Langley RG, Gupta A, Papp K, Wexler D, Østerdal ML, Curčič D. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222(2):148-156.
13. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154(6):1155-1160.
14. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217(4):321-328.
15. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25 Suppl 4:9-14.
16. Feldman SR, Horn EJ, Balkrishnan R, et al; International Psoriasis Council. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59(6):1009-1016.